At the same time, clinical observations have implicated IL-18 in various metabolic diseases including obesity, type 1 (T1D) and type 2 (T2D) diabetes, and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). Here, IL18 is linked to metabolic dysfunction-associated steatotic liver disease.